Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Soft Tissue and Bone Sarcomas
NCT00031915Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in soft tissue sarcoma (STS) and bone sarcoma, sponsored by National Cancer Institute. Primary endpoint: Response Rate. Started Jun 2002; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT00031915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031915.